DiagnosDGNOF +1.00%16 Gross Margin % is 6,958.33% as of Mar. 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 630 Healthcare Providers & Services companies, Diagnos ranks worse than 88.1% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Diagnos's Gross Profit for the
three
months ended in Mar. 2026 was $0.84 Mil. Diagnos's Revenue for the
three
months ended in Mar. 2026 was $0.01 Mil. Therefore, Diagnos's Gross Margin % for the quarter that ended in Mar. 2026 was 6,958.33%.
The historical rank and industry rank for Diagnos's Gross Margin % or its related term are showing as below:
DGNOF'
s Gross Margin % Range Over the Past 10 Years
Min: -492.94 Med: -79.2 Max: 48.08
Current: 16.92
During the past 13 years, the highestGross Margin % of Diagnos was 48.08%. The lowest was -492.94%. And the median was -79.20%.
DGNOF's Gross Margin % is ranked worse than 88.1% of 630
companies
in the Healthcare Providers & Services industry
Industry Median: 40.075
vs DGNOF: 16.92
Diagnos had a gross margin of 6,958.33% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Diagnos was 0.00% per year.
Diagnos (OTCPK:DGNOF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Diagnos had a gross margin of 6,958.33% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Diagnos Gross Margin % Related Terms
Diagnos Gross Margin % Historical Data
* Premium members only.
The historical data trend for Diagnos's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DGNOF vs VEEV, BTSG, TEM: Gross Margin % Comparison
For the Health Information Services subindustry, Diagnos's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Diagnos's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Diagnos (DGNOF) has a Gross Margin % of 6,958.33% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Diagnos and its competitors. According to the industry distribution chart, Diagnos ranks #555 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 88.1%.
Is Diagnos' Gross Margin % too high?
Diagnos' current Gross Margin % is 6,958.33%. The Healthcare Providers & Services industry median Gross Margin % is 40.08. Diagnos' value of 6,958.33% is 17263.3% above this industry median. Based on the distribution chart, Diagnos ranks #555 out of 630 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Gross Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #555 out of 630 companies for Gross Margin %. This places Diagnos in the lower half of its industry. The industry median Gross Margin % is 40.08. Diagnos' value of 6,958.33% is 17263.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.08, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnos's current Gross Margin % of 6,958.33% is 17263.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current Gross Margin % is 6,958.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current Gross Margin % is 6,958.33% and 17263.3% above the Healthcare Providers & Services industry median of 40.08. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Diagnos (DGNOF), the current Gross Margin % is 6,958.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
Gross Margin %: 6,958.33%
GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
Industry Position: 17263.3% above the Healthcare Providers & Services median (#555 of 630)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score
Get the complete analysis for DGNOF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
